Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
Zhang, Xuqing, Luo, Mengyao, Dastagir, Shamael R, Nixon, Mellissa, Khamhoung, Annie, Schmidt, Andrea, Lee, Albert, Subbiah, Naren, McLaughlin, Douglas C, Moore, Christopher L, Gribble, Mary, Bayhi, Nicholas, Amin, Viral, Pepi, Ryan, Pawar, Sneha, Lyford, Timothy J, Soman, Vikram, Mellen, Jennifer, Carpenter, Christopher L, Turka, Laurence A, Wickham, Thomas J, Chen, Tiffany F
Published in Nature communications (11.05.2021)
Published in Nature communications (11.05.2021)
Get full text
Journal Article
Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15
McArdel, Shannon L., Dugast, Anne-Sophie, Hoover, Maegan E., Bollampalli, Arjun, Hong, Enping, Castano, Zafira, Leonard, Shannon Curtis, Pawar, Sneha, Mellen, Jennifer, Muriuki, Kelvin, McLaughlin, Douglas C., Bayhi, Nicholas, Carpenter, Christopher L., Turka, Laurence A., Wickham, Thomas J., Elloul, Sivan
Published in Cancer Immunology, Immunotherapy (01.09.2021)
Published in Cancer Immunology, Immunotherapy (01.09.2021)
Get full text
Journal Article
Abstract 3260: Engineered red-cell therapeutics (RCT) as artificial antigen presenting cells promote in vivo expansion and anti-tumor activity of antigen specific T cells
Zhang, Xuqing, Dastagir, Shamael R., Subbiah, Naren, Luo, Mengyao, Soman, Vikram, Pawar, Sneha, McLaughlin, Douglas C., Bayhi, Nicholas, Amin, Viral, Nissen, Torben Straight, Carpenter, Christopher L., Wickham, Thomas J., Chen, Tiffany F.
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article